A Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Cancer

Trial Profile

A Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2015

At a glance

  • Drugs Irinotecan (Primary) ; Capecitabine
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 15 Oct 2014 Results published in the Media Release.
    • 09 Jul 2013 Status changed from recruiting to completed, as reported by a media release from Kinex Pharmaceuticals and Hanmi Pharmaceuticals.
    • 04 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top